Soleno Therapeutics Revenue 2011-2025 | SLNO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Soleno Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	-	-	1.45 M	388 K	-	3 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3 M	388 K	1.61 M

Quarterly Revenue Soleno Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
66 M	32.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-478 K	-355 K	-190 K	-	-	-	-	-	-	1 K	265 K	-	329 K	2 K	447 K	-	247 K	97 K	22 K	-	-	-	-	-	3 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
66 M	-478 K	7.29 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Diagnostics research industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Akumin AKU	750 M	-	-17.87 %	$ 25.9 M	Canada
Accelerate Diagnostics AXDX	2.97 M	-	-61.36 %	$ 2.46 M	USA
Centogene N.V. CNTG	128 M	-	-6.23 %	$ 30.6 M	Germany
Castle Biosciences CSTL	332 M	$ 38.85	2.32 %	$ 1.08 B	USA
DermTech DMTK	15.3 M	-	-11.32 %	$ 2.94 M	USA
Burning Rock Biotech Limited BNR	508 M	$ 16.36	-4.05 %	$ 176 M	China
Brainsway Ltd. BWAY	41 M	$ 17.05	-2.15 %	$ 99.4 M	Israel
Biocept BIOC	25.9 M	-	-13.05 %	$ 7.29 M	USA
Enzo Biochem ENZ	31.9 M	-	-8.98 %	$ 14.8 K	USA
Danaher Corporation DHR	23.9 B	$ 227.08	-2.28 %	$ 166 B	USA
Exact Sciences Corporation EXAS	2.76 B	$ 101.58	0.21 %	$ 18.8 B	USA
Fulgent Genetics FLGT	283 M	$ 27.13	0.26 %	$ 820 M	USA
BioNano Genomics BNGO	30.8 M	$ 1.63	-2.11 %	$ 2.07 M	USA
Oxford Immunotec Global PLC OXFD	73.7 M	-	-	$ 562 M	Britain
Heska Corporation HSKA	257 M	-	-	$ 1.31 B	USA
Chembio Diagnostics CEMI	49.5 M	-	0.22 %	$ 16.8 M	USA
DexCom DXCM	3.62 B	$ 66.91	-2.94 %	$ 25.8 B	USA
DarioHealth Corp. DRIO	20.4 M	$ 11.92	-6.58 %	$ 338 M	Israel
Illumina ILMN	4.37 B	$ 134.29	-1.58 %	$ 21.4 B	USA
IQVIA Holdings IQV	15.4 B	$ 221.54	-1.96 %	$ 40.2 B	USA
Global Cord Blood Corporation CO	1.24 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	138 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	6.79 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	651 M	-	0.12 %	$ 80.1 M	China
PRA Health Sciences, Inc. PRAH	3.18 B	-	-	$ 10.7 B	USA
Lantheus Holdings LNTH	1.53 B	$ 66.11	4.76 %	$ 4.57 B	USA
Guardant Health GH	739 M	$ 102.09	0.7 %	$ 12.5 B	USA
CareDx, Inc CDNA	280 M	$ 20.44	3.23 %	$ 1.1 B	USA
Anixa Biosciences ANIX	210 K	$ 3.59	-25.21 %	$ 115 K	USA
Co-Diagnostics CODX	6.81 M	$ 0.34	-2.96 %	$ 9.98 M	USA
Myriad Genetics MYGN	838 M	$ 7.26	-0.62 %	$ 658 M	USA
Neogen Corporation NEOG	895 M	$ 6.86	-2.63 %	$ 1.49 B	USA
National Research Corporation NRC	149 M	$ 17.81	2.24 %	$ 437 M	USA
Invitae Corporation NVTA	122 M	-	-	$ 21.2 M	USA
Aspira Women's Health AWH	8.18 M	-	-6.19 %	$ 10.5 M	USA
Laboratory Corporation of America Holdings LH	13 B	$ 263.51	-0.46 %	$ 22.1 B	USA
Organovo Holdings ONVO	144 K	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	5.2 M	-	-16.95 %	$ 1.54 M	USA
Pacific Biosciences of California PACB	201 M	$ 2.13	-1.61 %	$ 540 M	USA
Koninklijke Philips N.V. PHG	18 B	$ 26.6	-1.52 %	$ 20 B	Niderland
Psychemedics Corporation PMD	22.1 M	-	-1.84 %	$ 15.3 M	USA
Charles River Laboratories International CRL	4.05 B	$ 192.57	-0.96 %	$ 9.89 B	USA
Quidel Corporation QDEL	1.66 B	$ 28.79	-2.93 %	$ 1.21 B	USA
Quotient Limited QTNT	43.4 M	-	-11.32 %	$ 1.1 M	Schweiz
RadNet RDNT	1.83 B	$ 75.0	-4.65 %	$ 5.48 B	USA
HTG Molecular Diagnostics HTGM	6.37 M	-	-20.0 %	$ 1.06 M	USA
Quest Diagnostics Incorporated DGX	9.87 B	$ 182.21	0.35 %	$ 20.2 B	USA
Biodesix BDSX	71.3 M	$ 7.94	-1.0 %	$ 1.03 B	USA
ICON Public Limited Company ICLR	5.48 B	$ 186.28	-1.92 %	$ 15.4 B	Irlanda